Metabolic dysfunction-associated steatohepatitis research hub
4 indexed studies · 2 currently recruiting
- authorisedTherapeutic use (Phase IV)
Reducing Non-Alcoholic Steatohepatitis
This study is looking at how a medicine called Jardiance might help people with a liver condition called non-alcoholic steatohepatitis (NASH). Researchers want to see if it can improve liver health and reduce liver scarring, which is common in NASH.
Czechia - active not recruitingPHASE2
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
This study is looking into a new medicine called efinopegdutide for a liver condition called MASH. We want to see if it can help reduce liver fat, swelling, and scarring in people with MASH and mild scarring. It also checks how safe the medicine is.
United States · Australia · Canada - recruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is testing a new drug called ALN-CIDEB for people with fatty liver conditions, MASLD and MASH. It aims to check how safe the drug is, if it causes side effects, and how it affects liver fat.
United States · United Kingdom